Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis

NCT06137183 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06137183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06137183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 1, 2024
Completion date
June 16, 2025
Enrollment
79 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis